|
|
|||||||||||||||
|
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español | |||||||||
| Pàgina inicial > Articles > Articles publicats > Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly |
| Data: | 2020 |
| Resum: | Midlife obesity is a risk factor for dementia. We investigated the impact of obesity on brain structure, metabolism, and cerebrospinal fluid (CSF) core Alzheimer's disease (AD) biomarkers in healthy elderly. We selected controls from ADNI2 with CSF AD biomarkers and/or fluorodeoxyglucose positron emission tomography (FDG-PET) and 3T-MRI. We measured cortical thickness, FDG uptake, and CSF amyloid beta (Aβ)1-42, p-tau, and t-tau levels. We performed regression analyses between these biomarkers and body mass index (BMI). We included 201 individuals (mean age 73. 5 years, mean BMI 27. 4 kg/m 2). Higher BMI was related to less cortical thickness and higher metabolism in brain areas typically not involved in AD (family-wise error [FWE] <0. 05), but not to AD CSF biomarkers. It is notable that the impact of obesity on brain metabolism and structure was also found in amyloid negative individuals. In the cognitively unimpaired elderly, obesity has differential effects on brain metabolism and structure independent of an underlying AD pathophysiology. |
| Ajuts: | Instituto de Salud Carlos III PI14-01126 Instituto de Salud Carlos III PI17-01019 Instituto de Salud Carlos III PI13-01532 Instituto de Salud Carlos III PI16-01825 Instituto de Salud Carlos III PI18-00335 Instituto de Salud Carlos III PI18-00435 Instituto de Salud Carlos III PI14-1561 Instituto de Salud Carlos III PI17-01896 Instituto de Salud Carlos III PI17-00279 Instituto de Salud Carlos III FI18-00275 Agència de Gestió d'Ajuts Universitaris i de Recerca SLT006-17-00119 Agència de Gestió d'Ajuts Universitaris i de Recerca SLT006-17-00125 Agència de Gestió d'Ajuts Universitaris i de Recerca SLT008-18-00127 |
| Nota: | Altres ajuts: This study was supported by the CIBERNED program (Program 1, Alzheimer Disease SIGNAL study, www.signalstudy.es); and partly jointly funded by Fondo Europeo de Desarrollo Regional, Unión Europea, Una manera de hacer Europa. This work was also supported by the National Institutes of Health (NIA grants 1R01AG056850 - 01A1; R21AG056974, and R01AG061566), Fundació La Marató de TV3 (20141210, 044412). This work was also supported by the Fundació Bancaria La Caixa."Ajut a la Recerca Josep Font" (Hospital Clinic de Barcelona). Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). [...]. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). |
| Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. |
| Llengua: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Matèria: | Body mass index ; Cerebrospinal fluid Alzheimer's disease biomarkers ; Fluorodeoxyglucose PET ; Magnetic resonance imaging ; Obesity ; Pre-clinical Alzheimer's disease |
| Publicat a: | Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring, Vol. 12 (july 2020) , ISSN 2352-8729 |
9 p, 2.2 MB |